Actress Jamie-Lynn Sigler has multiple sclerosis (colloquially known as MS), and that's precisely why she's starring in the ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

This copy is for your personal, non-commercial use only ... the active ingredient in the company’s blockbuster Ozempic and Wegovy diabetes and weight-loss drugs, and was tested in the trial ...

Calorie-managed diets and exercise have been the mainstay approach of commercial weight loss programs for decades. But as weight loss medications like Ozempic, Wegovy and others become household ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

Ozempic and Wegovy may not have been developed if not for the insistence of Novo Nordisk's head of research, Mads Krogsgaard. Leadership at the Danish company in the early 1990s were skeptical ...

Ozempic (semaglutide) and Wegovy (semaglutide) are prescription drugs that may be used to help with long-term weight loss. But only Wegovy is FDA-approved for this use. Both drugs are approved for ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analog class, better known under the trade names Ozempic and Wegovy, is remarkable ...

Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply ...

The demand for weight loss operations dropped sharply last year as the number of people opting for anti-obesity drugs such as Wegovy and Saxenda more than doubled, a study published Friday found.